Drug Trial Radar · NCT07531251
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jul 2, 2026
Primary completion
Sep 30, 2029
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Stealth BioTherapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 5 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3b/4, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of a once daily SC injection of elamipretide in subjects with genetically confirmed BTHS for 72 weeks. The primary trial objective is to confirm the efficacy of elamipretide which is approved in the United States(FORZINITY™) under the accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint.
Conditions
- Barth Syndrome
Interventions
ElamipretideDrug
sub cutaneous injection
PlaceboDrug
sub cutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy End PointTime frame: 72 weeks
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Trial Not Offered in the U.S
Needham, Massachusetts · Terminated
Children's Hospital of Westmead
Westmead, North South Wales, Australia · Recruiting
Metabolics and Genetics in Canada (MAGIC)
Calgary, Alberta, Canada · Recruiting
Bristol Royal Hospital for Children Upper Maudlin Street Paul O'Gorman Building
Bristol, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.